دورية أكاديمية
أعرض في EDS

Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy.

التفاصيل البيبلوغرافية
العنوان: Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy.
المؤلفون: Surapaneni SK; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., Patel N; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., Sun L; Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, 32306-4300, USA., Kommineni N; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., Kalvala AK; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., Gebeyehu A; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., Arthur P; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., Duke LC; Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, 32306-4300, USA., Nimma R; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA., G Meckes D Jr; Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, 32306-4300, USA., Singh M; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 32307, USA. mandip.sachdeva@gmail.com.
المصدر: Drug delivery and translational research [Drug Deliv Transl Res] 2022 Nov; Vol. 12 (11), pp. 2762-2777. Date of Electronic Publication: 2022 Feb 25.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York : Springer
مواضيع طبية MeSH: Cannabidiol*/pharmacology , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/metabolism, Apoptosis ; Autophagy ; Beclin-1/metabolism ; Beclin-1/pharmacology ; Caspase 9/metabolism ; Caspase 9/pharmacology ; Cell Line, Tumor ; Cell Proliferation ; Doxorubicin/pharmacology ; Fibronectins ; Humans ; Hydrogels ; Integrin alpha5/metabolism ; Integrin alpha5/pharmacology ; Vimentin/metabolism ; Vimentin/pharmacology
مستخلص: To date, promising therapy for triple negative breast cancer (TNBC) remains a serious concern clinically because of poor prognosis, resistance, and recurrence. Herein, anti-cancer potential of synthetic cannabidiol (CBD; Purisys, GA; GMP grade) was explored either alone or as a chemosensitizer followed by post-treatment with doxorubicin (DOX) in TNBC (i.e., MDA-MB-231 and MDA-MB-468) cells. In comparison to 2D cultures, CBD showed greater IC 50 values in 3D (LDP2 hydrogel based) cultures of MDA-MB-231 (6.26-fold higher) and MDA-MB-468 (10.22-fold higher) cells. Next-generation RNA sequencing revealed GADD45A, GADD45G, FASN, LOX, and integrin (i.e., -α5, -β5) genes to be novelly altered by CBD in MDA-MB-231 cells. CIM-16 plate-based migration assay and western blotting disclosed that CBD induces anti-migratory effects in TNBC cells by decreasing fibronectin, vimentin, and integrins-α5, -β5, and -β1. Western blotting, RT-qPCR, and immunocytochemistry revealed that CBD inhibited autophagy (decreased Beclin1, and ATG-5, -7, and -16) of TNBC cells. CBD pre-treatment increased DOX sensitivity in TNBC cells. CBD pre-treatment accompanied by DOX treatment decreased LOX and integrin-α5, and increased caspase 9 protein respectively in MDA-MB-468 cells.
(© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.)
References: Sci Rep. 2020 Oct 21;10(1):17954. (PMID: 33087811)
Int J Cancer. 2005 Jun 20;115(3):403-11. (PMID: 15688367)
Cancer Res. 1998 Apr 1;58(7):1332-7. (PMID: 9537224)
Pharm Res. 2013 May;30(5):1435-46. (PMID: 23361589)
PLoS One. 2014 Jan 28;9(1):e87092. (PMID: 24489842)
Cancer Res. 1989 Jul 15;49(14):3976-84. (PMID: 2660984)
JAMA Oncol. 2016 Jun 1;2(6):751-60. (PMID: 26914222)
Toxicol Appl Pharmacol. 2020 Aug 15;401:115112. (PMID: 32540278)
Nat Cell Biol. 2014 Apr;16(4):301-2. (PMID: 24691256)
Int J Pharm. 2020 Jan 25;574:118916. (PMID: 31811927)
Cancer Res. 2006 Sep 1;66(17):8448-54. (PMID: 16951155)
J Transl Med. 2013 May 24;11:131. (PMID: 23706118)
PLoS One. 2013;8(1):e53708. (PMID: 23349734)
Cancer Res. 2011 Mar 1;71(5):1742-51. (PMID: 21343398)
Life Sci. 2015 Jun 1;130:73-80. (PMID: 25817229)
Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016. (PMID: 28922023)
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):49-57. (PMID: 27842219)
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. (PMID: 26667886)
Oncol Rep. 2014 Sep;32(3):935-42. (PMID: 24994549)
Fitoterapia. 2018 Sep;129:383-400. (PMID: 29476786)
Oncol Lett. 2017 Dec;14(6):6999-7010. (PMID: 29344128)
Drugs. 2000 Dec;60(6):1303-14. (PMID: 11152013)
Sci Rep. 2017 Nov 20;7(1):15824. (PMID: 29158480)
Sci Rep. 2018 Aug 16;8(1):12295. (PMID: 30115982)
Cell Cycle. 2020 May;19(9):961-989. (PMID: 32249682)
Mutat Res. 2005 Jan 6;569(1-2):133-43. (PMID: 15603758)
Breast Cancer Res Treat. 2011 Aug;129(1):37-47. (PMID: 20859676)
Genet Mol Res. 2015 May 25;14(2):5621-9. (PMID: 26125760)
Assay Drug Dev Technol. 2014 May;12(4):207-18. (PMID: 24831787)
Anticancer Drugs. 2018 Jan;29(1):1-9. (PMID: 29099416)
J Biol Chem. 2002 May 10;277(19):16464-9. (PMID: 11815623)
BMC Cancer. 2018 Jan 6;18(1):41. (PMID: 29304770)
Nano Lett. 2017 Nov 8;17(11):6941-6948. (PMID: 29022351)
Br J Pharmacol. 2010 Aug;160(7):1577-9. (PMID: 20649561)
Mol Cancer Ther. 2007 Nov;6(11):2921-7. (PMID: 18025276)
Oncotarget. 2015 Aug 28;6(25):21255-67. (PMID: 26101913)
Curr Oncol. 2016 Mar;23(2):S15-22. (PMID: 27022310)
Clin Cancer Res. 2008 Dec 15;14(24):8010-8. (PMID: 19088017)
Nat Genet. 1999 Oct;23(2):176-84. (PMID: 10508513)
Int J Cancer. 2020 Nov 1;147(9):2587-2596. (PMID: 32488875)
Pezcoller Found J. 2007 Oct;16(29):2-17. (PMID: 21132084)
Int J Pharm. 2021 Sep 25;607:120943. (PMID: 34324983)
Phytomedicine. 2014 Apr 15;21(5):631-9. (PMID: 24373545)
Cancer Lett. 2009 Nov 18;285(1):6-12. (PMID: 19442435)
Int J Cancer. 2006 Apr 15;118(8):1922-9. (PMID: 16287078)
Curr Opin Genet Dev. 2014 Feb;24:68-73. (PMID: 24657539)
Cell. 2018 Jan 11;172(1-2):373-386.e10. (PMID: 29224780)
Cancer Ther. 2009;7(A):268-276. (PMID: 19652693)
Oxid Med Cell Longev. 2015;2015:358396. (PMID: 25838866)
Mol Oncol. 2015 Apr;9(4):906-19. (PMID: 25660577)
Gene. 2015 Nov 1;572(1):79-86. (PMID: 26164760)
Br J Cancer. 2004 Jun 14;90(12):2411-7. (PMID: 15150577)
J Int Med Res. 2020 Nov;48(11):300060520968299. (PMID: 33238786)
Cancer Res. 2007 Jan 15;67(2):659-64. (PMID: 17234776)
Cancer Res. 2016 Jan 15;76(2):188-92. (PMID: 26732355)
Pharmacol Rev. 2006 Sep;58(3):621-81. (PMID: 16968952)
Curr Pharm Des. 2021;27(7):996-1005. (PMID: 33349212)
Mol Cancer. 2019 Apr 5;18(1):82. (PMID: 30953511)
Eur J Cancer. 2002 Dec;38(18):2362-70. (PMID: 12460779)
Ther Adv Psychopharmacol. 2012 Dec;2(6):241-54. (PMID: 23983983)
PLoS Pathog. 2020 Dec 31;16(12):e1009023. (PMID: 33382850)
Nucleic Acids Res. 2019 Jul 2;47(W1):W234-W241. (PMID: 30931480)
Nat Commun. 2020 May 15;11(1):2416. (PMID: 32415208)
Sci Rep. 2020 Nov 26;10(1):20622. (PMID: 33244087)
Oncogene. 2013 Jun 20;32(25):3049-58. (PMID: 22824793)
J Oncol Pharm Pract. 2020 Jul;26(5):1117-1127. (PMID: 31707922)
Pharmacol Rep. 2020 Dec;72(6):1627-1644. (PMID: 32720218)
Mol Cancer Ther. 2014 Dec;13(12):2955-67. (PMID: 25398831)
Toxicol In Vitro. 2020 Feb;62:104695. (PMID: 31639451)
Breast. 2018 Oct;41:34-41. (PMID: 30007266)
Mol Cell Biol. 2016 Apr 15;36(9):1383-94. (PMID: 26929200)
Carcinogenesis. 2013 Jan;34(1):48-57. (PMID: 23079154)
Science. 2013 Feb 15;339(6121):819-23. (PMID: 23287718)
Brief Bioinform. 2019 Nov 27;20(6):2044-2054. (PMID: 30099484)
Am J Cancer Res. 2015 Dec 15;6(1):97-104. (PMID: 27073727)
Onco Targets Ther. 2016 Nov 22;9:7207-7218. (PMID: 27920558)
Expert Opin Biol Ther. 2020 Sep;20(9):981-989. (PMID: 32450725)
معلومات مُعتمدة: G12 MD007582 United States MD NIMHD NIH HHS; U54 MD007582 United States MD NIMHD NIH HHS
فهرسة مساهمة: Keywords: Autophagy; Cannabidiol; Doxorubicin; GADD45α; Integrins; TNBC
المشرفين على المادة: 0 (Beclin-1)
0 (Fibronectins)
0 (Hydrogels)
0 (Integrin alpha5)
0 (Vimentin)
19GBJ60SN5 (Cannabidiol)
80168379AG (Doxorubicin)
EC 3.4.22.- (Caspase 9)
تواريخ الأحداث: Date Created: 20220226 Date Completed: 20220928 Latest Revision: 20230302
رمز التحديث: 20230302
مُعرف محوري في PubMed: PMC9811521
DOI: 10.1007/s13346-022-01137-2
PMID: 35217991
قاعدة البيانات: MEDLINE
الوصف
تدمد:2190-3948
DOI:10.1007/s13346-022-01137-2